RESUMEN
To investigate the efficacy and safety of Fuzheng Huayu Jiaonang (FZ) and Anluo Huaxian Wan (AL) in the treatment of chronic hepatitis B liver fibrosis. Jadad scoring method was adopted to evaluate the quality of literature, Rev Man 5.3 software was used for Meta-analysis, and indirect comparison was carried out by ITC software. The randomized controlled trials (RCTs) were collected for comparing FZ and AL in treatment of chronic hepatitis B with liver fibrosis. With ETV as the common control, they were compared through indirect Meta-analysis (ITC). Finally, 15 articles (10 FZ, 5 AL) involving 1 316 patients were included. According to the indirect comparison, FZ combined with ETV had significant improvements in hyaluronic acid, laminin, procollagen type â ¢, and collagen type â £. AL combined with ETV had significant improvements in laminin, procollagen type â ¢, collagen type â £, but with no difference in hyaluronic acid. The safety of AL was higher than that of FA. The limited evidences in this study showed that Anluo Huaxian Wan had a higher safety than Fuzheng Huayu Jiaonang, but a lower total efficiency. Due to the low quality of the included RCTs, these two medicines shall be comprehensively compared in further high-quality clinical trials.